We noticed you are on our US page. Want to switch regions? Choose from the options:

  • Healthcare Professionals
  • Latest research
  • Publications
  • The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Paralle.

The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Paralle

Shore Neal D., MD, FACS, Dearnaley David P, Saltzstein Daniel R, Sylvester John E, Karsh Lawrence, Mehlhaff Bryan A, Pieczonka Christopher, Bailen James L, Shi Hongliang, Ye Zhan, Faessel Hélène M, Lin Huamao, Zhu Yanyan, Saad Fred, MacLean David B